Unusual Options Activity: Amgen (AMGN)

Amgen (AMGN)

Bet on shares moving 20 percent higher by late January.

The January 17th 2020 $280 call options on Amgen (AMGN) saw a 21-fold increase in volume with over 3,100 contracts trading hands. Shares of the company would need to rally about 19 percent from their current price near $234 for this out-of-the-money call to expire with any value.

The option buyer paid around $0.10, or just $10 per contract, so it’s a cheap bet on shares moving higher in the next few weeks.

  • Special: Turn $10,000 Into $1 Million With Just One Stock
  • Even if shares don’t hit the $280 strike price, a sharp rally could lead to a quick double or triple from current prices.

    The diversified pharmaceutical manufacturer has seen shares beat the S&P 500 in the past year by three points, amidst a tough year for the space in general.

    Shares are well-valued at just under 15 times forward earnings, and the company has a huge 34.5 percent profit margin. Today’s shareholder can also get a 2.5 percent dividend yield.

    Action to take: Long-term, we like shares here up to $240.00. However, the pharma space isn’t one that often provides huge swings upward, even if the entire sector is oversold right now, so we’re a bit skeptical that the soon-to-expire January option will make traders a profit.

    A better trade may be the July 2020 $250 calls. They’re a lot more expensive near $9, or $900 per contract, but they have a better chance of moving in-the-money rather than betting on a $0.10 option to double or triple in just the next few weeks.

    • No. 1 Commodity Stock to Buy in 2020

      Hint: It’s not silver, platinum or any other precious metal. It’s not aluminum, nickel, iron ore or lithium, either.

      But without it, we couldn’t make airplanes, automobiles, batteries, boats, cosmetics, computers, surgical tools or smartphones.

      Yet this metal could soon experience the greatest supply crunch in history … which could launch its price to levels never seen before.

      Read the full story here…